Physician Payments from Pharmaceutical Companies Related to Cancer Drugs - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35946837/
doi: 10.1093/oncolo/oyac160. Online ahead of print. 1 Health Outcomes Research Group, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 2 Delfi Diagnostics, Baltimore, MD,...
Conclusions: Although industry-sponsored education may also serve marketing purposes, the absence of association between industry payments and Medicare spending and the decline in payments subsequent to approval are consistent with claims that industry payments function to facilitate physician education.
-
Albert Dekker3yrthis topic continues to be controversial as the purpose of education is to increase prescribing
Clinical factors associated with outcome in solid tumor patients treated with immune-checkpoint inhibitors: a single institution retrospective analysis - Discover Oncology
Source : https://link.springer.com/article/10.1007/s12672-022-00538-6
Objectives Response to immune checkpoint inhibitor (ICI) remains limited to a subset of patients and predictive biomarkers of response remains an unmet need, limiting our ability to provide precision medicine....
Conclusions: Mechanisms underlying the clinical predictors of response observed in this real-world analysis, such as genetic variants and bone metastasis-tumor microenvironment, warrant further exploration in larger studies incorporating translational endpoints. Consistently positive clinical correlates may help inform patient stratification...
T790M mutation positive squamous cell carcinoma transformation from EGFR-mutated lung adenocarcinoma after low dose erlotinib: A case report and literature review - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35960133/
Rationale: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are widely used for the treatment of EGFR mutation positive advanced nonsmall cell lung cancer (NSCLC); however, acquired resistance is...
Lesson: The literature review and our report suggest that osimertinib is a promising treatment for NSCLC regardless of histology if T790M is present as an acquired mutation.
Heterogeneous expression of ACE2, TMPRSS2, and FURIN at single-cell resolution in advanced non-small cell lung cancer - Journal of Cancer Research and Clinical Oncology
Source : https://link.springer.com/article/10.1007/s00432-022-04253-1
Purpose Considering the high susceptibility of patients with advanced non-small cell lung cancer (NSCLC) to COVID-19, we explored the susceptible cell types and potential routes of SARS-CoV-2 infection in lung...
Conclusion: Our research first revealed the heterogeneous expression of ACE2, TMPRSS2, and FURIN in different cell subsets of NSCLC and also across different individuals. These results provide insight into the specific cells targeted by SARS-CoV-2 (i.e., cancer cells and alveolar cells) in patients with advanced NSCLC, and indicate that smoking...
Pneumothorax in lung cancer following anlotinib treatment: A case report
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9302245/
Anlotinib is an oral tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor, and has been approved for the treatment of patients with advanced nonsmall cell lung cancer who had...
Lessons: Pneumothorax may occur when VEGF is inhibited, which can promote the proliferation and repair of alveolar wall substances, leading to alveolar rupture. With respect to pneumothorax, it is necessary to be aware of the risk of pulmonary bullous rupture during antitumor treatment with small-molecule tyrosine kinase drugs.
-
Albert Dekker4yrNever seen it; obviously everything is possible; it though does appear it is more of the issue for those with severe CPOD at baseline